Insider buying last 90 days
No open-market insider purchases were filed for DGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DGX insider filing, plotted on the chart in Gekko.Open DGX in Gekko
NYSE: DGX
Quest Diagnostics (DGX) Stock Analysis & Forecast
Nov 4 close
$255.68+8.62 (+3.5%)
Gekko Brief
AI summaryNov 4 closeQuest Diagnostics shares rose this week, outperforming the broader market even as the S&P 500 and Dow Jones Industrial Average declined, extending gains following Q3 2026 results that showed revenue growth of 10% and adjusted EPS growth exceeding 15%, with strength across physician, hospital and consumer channels including Co-Lab Solutions with Corewell Health and a new Apple Health app integration. The company also faces a newly filed class action lawsuit alleging a data breach tied to its Quanum LSM system, while a director and an officer each filed to sell shares acquired through options and plans.
DGX closed at $255.68, up 3.5%, sitting above both its 50-day average of $238.95 and its 200-day average of $213.07, with the 50-day above the 200-day. The stock trades near its 52-week high of $256.99. The GekkoIndex reads 48.6, placing it in the Neutral zone, while the price sits 11.8% above Gekko Fair Value of $228.68.
The next earnings date falls on 9 February 2027, outside a typical 20-trading-day hold. Smart money activity over the past 90 days shows one Congressional buy and no sales, alongside one billionaire holder. Seasonality data shows the next 20 trading days have averaged a 4.6% return over 5 years, rising in 5 of them. Analyst consensus among 6 firms shows 3 buy and 3 hold ratings, with a consensus target of $257.27.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Quest Diagnostics price vs fair value
Close $255.68200-day averageGekko Fair Value $228.68
Quest Diagnostics quick facts
- Market cap
- $28.22B
- P/E ratio
- 25
- Forward P/E
- 21
- EPS, TTM
- $10.04
- Revenue, TTM
- $11.84B
- Profit margin
- 9.5%
- Dividend yield
- 1.34%
- Beta
- 0.55
- Volume
- 915,715 avg 1.00M
- 1-year return
- +43.0%
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±4%
- 50-day average
- $238.95
- 200-day average
- $213.07
- Next earnings
- Feb 9 before open
- Shares outstanding
- 110.4M
Quest Diagnostics swing-trade checklist
Quest Diagnostics scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $255.68 is above the 50-day ($238.95) and 200-day ($213.07) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
48.6, Neutral
Reading 48.6 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
11.8% above
Price is 11.8% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 96 days
Next report Feb 9, 2027, 96 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.6% on average
From this point in the calendar, the next 20 trading days averaged +4.6% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Quest Diagnostics stock chart and price history
Quest Diagnostics closed at $255.68 on Nov 4, 2026, +43.0% over the past year, inside a 52-week range of $171.18 to $256.99.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +11.9%
- 3 months
- +7.2%
- 6 months
- +35.2%
- 1 year
- +43.0%
The full DGX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DGX in Gekko
Follow Quest Diagnostics through every session
Put DGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DGX in GekkoFree for 7 days. No credit card required.
About Quest Diagnostics
Quest Diagnostics runs testing laboratories that analyze patient samples and turn them into clinical information for doctors, hospitals, and other healthcare groups, both within the United States and in other countries. Its work spans everyday lab work along with more specialized clinical and pathology testing, and the company has built its reputation around this kind of diagnostic reporting.
Alongside its main brand, Quest Diagnostics also operates under names such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, which help it connect with different segments of the healthcare world, including health plans, employers, integrated care networks, and direct medical providers. To get samples and results moving, it relies on a mix of lab sites, patient service locations, in-office blood draw staff, call centers, and traveling health workers such as nurses and paramedics. The company also performs risk evaluation work for life insurers and builds software and IT tools used by clinicians and healthcare organizations.
Quest Diagnostics traces back to 1967 and keeps its headquarters in Secaucus, New Jersey. Its stock trades on the NYSE under the ticker DGX.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Services to the health industry
- Website
- questdiagnostics.com
Quest Diagnostics GekkoIndex: the smart money zone
Quest Diagnostics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.6, in the Neutral zone, down 2.8 points over five sessions.
48.6Neutral
Down 2.8 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 18 | +1.0% | +1.6% | ||
| Accumulation | 192 | +1.1% | +4.0% | ||
| Neutral (current zone) | 456 | +0.3% | +1.2% | ||
| Distribution | 30 | −1.0% | +0.9% | ||
| Selling | 1 | Too few readings yet | |||
Average DGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the DGX price, zone by zone.Track DGX in Gekko
Is Quest Diagnostics stock overvalued? Gekko Fair Value
Quest Diagnostics trades 11.8% above Gekko Fair Value of $228.68, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Quest Diagnostics shares are worth, recalculated every trading day.
$228.68
Gekko Fair Value, Nov 4, 2026
11.8% Overvalued
At the end of Aug 2026 the price was 6.2% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open DGX in Gekko
Quest Diagnostics insider and Congress trading
No open-market insider purchases were filed for Quest Diagnostics, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Quest Diagnostics has been buying back its own shares.
- Latest authorization
- $1.00B, Feb 10, 2026
- Bought back, quarter ended Sep 30, 2026
- $150.0M
- As a share of market cap
- 0.53%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds DGX.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Quest Diagnostics earnings: next date and track record
Quest Diagnostics reports on Feb 9, 2027, before the open (96 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 9, 2027
Expected before the open, 96 days away
- EPS estimate
- $2.68
- Revenue estimate
- $3.04B
8 of 8reports beat the EPS estimate
±5.3%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 22, 2026 AI summary
- What they said
- Quest Diagnostics reported Q3 2026 revenue growth of 10% and adjusted EPS growth exceeding 15%, driven by strength across physician, hospital, and consumer channels. Hospital revenue grew double digits from Co-Lab Solutions with Corewell Health; physician channel delivered high single-digit growth. Consumer health is tracking above 30% full-year growth, bolstered by a new Apple Health app integration for direct lab ordering across 50+ biomarkers. Advanced diagnostics also posted double-digit revenue growth.
- Guidance
- Management raised full-year guidance for both revenues and adjusted EPS, citing continued organic growth momentum. Consumer health expected to exceed 30% growth for the full year. A Northeastern U.S. health system outreach asset acquisition is expected to close before year-end.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 22, 2026 | $3.00 est $2.87 | $3.10B est $3.05B | +1.2% |
| Jul 23, 2026 | $3.12 est $2.81 | $3.04B est $2.97B | +8.6% |
| Apr 21, 2026 | $2.50 est $2.37 | $2.90B est $2.83B | +3.9% |
| Feb 10, 2026 | $2.42 est $2.36 | $2.81B est $2.75B | +9.4% |
| Oct 21, 2025 | $2.60 est $2.50 | $2.82B est $2.74B | −4.9% |
| Jul 22, 2025 | $2.62 est $2.57 | $2.76B est $2.73B | +2.4% |
| Apr 22, 2025 | $2.21 est $2.15 | $2.65B est $2.63B | +7.2% |
| Jan 30, 2025 | $2.23 est $2.18 | $2.62B est $2.58B | +4.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Quest Diagnostics stock forecast and analyst price targets
Analysts’ average 12-month price target for Quest Diagnostics is $257.27, +0.6% from the last close, from 6 firms rating the stock in the last 90 days.
$257.27consensus 12-month target, +0.6% from the last close
Now $255.68Avg $257.27
Low $250High $265
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 23 | Barclays | $260 | +1.7% |
| Oct 23 | Robert W. Baird | $262 | +2.5% |
| Oct 23 | Morgan Stanley | $260 | +1.7% |
| Oct 22 | Bank of America Securities | $265 | +3.6% |
| Oct 19 | UBS | $250 | −2.2% |
+1.2%average 20-day move after past Neutral readings
+4.6%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Quest Diagnostics seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Quest Diagnostics averaged +4.6% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.5% | 4 of 5 |
| Next 10 trading days | +2.9% | 5 of 5 |
| Next 15 trading days | +5.2% | 5 of 5 |
| Next 20 trading days | +4.6% | 5 of 5 |
| Next 30 trading days | +5.5% | 5 of 5 |
For scale, DGX’s typical 20-trading-day move in either direction is about 4%.
Quest Diagnostics market cap and key statistics
Quest Diagnostics’s market cap is $28.22B, with a P/E ratio of 25 and revenue of $11.84B over the last twelve months.
Valuation
- Market cap
- $28.22B
- P/E ratio
- 25
- Forward P/E
- 21
- EPS, TTM
- $10.04
- Gekko Fair Value
- $228.68
Trading
- Volume
- 915,715
- Avg volume, 20 days
- 1.00M
- 52-week high
- $256.99
- 52-week low
- $171.18
- Shares outstanding
- 110.4M
Financials
- Revenue, TTM
- $11.84B
- Profit margin
- 9.5%
- Return on equity
- 15.3%
- Quarterly earnings growth, YoY
- +28.7%
Risk and income
- Beta
- 0.55
- Typical daily move
- ±2.9%
- Typical 20-day move
- ±4%
- Dividend yield
- 1.34%
Quest Diagnostics stock news this week
Coverage of Quest Diagnostics this week reads neutral: 2 positive, 5 neutral and 2 negative headlines.
- An officer proposes selling 22,105 Quest Diagnostics (DGX) shares acquired through stock options.Stock Titan, Nov 3
- Quest Diagnostics (DGX) Stock Price, Chart & Analysiswww.debelegger.nl, Nov 2
- Quest Diagnostics Incorporated (DGX) Seasonal returns chartYahoo Finance UK, Oct 31
- Quest Diagnostics stock at EUR 227.05 in late October 29 quotead-hoc-news.de, Oct 30
- Quest Diagnostics Inc. stock outperforms competitors on strong trading dayMarketWatch, Oct 29
- Quest Diagnostics experienced a data breach, a new class action claims.Claim Depot, Oct 29
Quest Diagnostics peers
Quest Diagnostics’s 2 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| ASTHAstrana Health | Neutral | 24.0% below |
| NRCNational Research | Distribution | 36.2% above |
A peer links to its own page where one exists.
Quest Diagnostics stock FAQ
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $28.22B at the Nov 4, 2026 close of $255.68, with 110.4M shares outstanding. The shares trade on a P/E ratio of 25.
What is the Quest Diagnostics stock forecast?
The consensus analyst 12-month price target for Quest Diagnostics is $257.27, +0.6% from the last close. Of the 6 firms that rated the stock in the last 90 days, 3 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Quest Diagnostics stock overvalued or undervalued?
On Gekko’s estimate Quest Diagnostics is overvalued: the Nov 4, 2026 close of $255.68 is 11.8% above Gekko Fair Value of $228.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Quest Diagnostics report earnings next?
Quest Diagnostics is expected to report on Feb 9, 2027, before the market opens (96 days away). Analysts expect earnings of $2.68 per share on revenue of $3.04B. Quest Diagnostics beat the earnings estimate in 8 of its last 8 reports, moving 5.3% on average across the report.
What is Quest Diagnostics’s 52-week high and low?
Quest Diagnostics’s 52-week high is $256.99 and its 52-week low is $171.18; it closed at $255.68 on Nov 4, 2026, +43.0% over the past year.
Is Quest Diagnostics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Quest Diagnostics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.